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Introduction: Mutations of RyR2 gene encoding calcium channel of sarcoplazmatic
reticulum are the cause of congenital catecholaminergic polymorphic ventricular
tachycardia. The aim of this study was to test the hypothesis that RyR2 variants can
increase occurrence of malignant arrhythmias in patients with structural heart diseases.
Methods: The investigated group consisted of 36 patients with structural heart diseases
with ICD implanted who suffered arrhythmic storm. In the control group there were 141
patients with coronary artery disease who were hospitalized at our department owing to an
acute coronary event and they were alive at least 3 years after the index event. Thus, they
could be considered as a group with a low risk of sudden cardiac death. In all of them
mutation analysis of RyR2 gene was performed.
Results: We detected 16 different sequence changes of RyR2 gene in both groups. None of
the found nucleotide polymorphisms led to amino acid changes, were located close to
splice sites or had any similarity to known splicing enhancer motifs. The occurrence of
these variants was not different in both groups.
Conclusions: The prevalence of RyR2 gene variants was not different in cases versus controls
suggesting a limited role of this gene in the arrhythmogenesis in structural heart disease
patients.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Introduction
The leading cause of cardiovascular mortality is sudden
cardiac death (SCD). Estimated incidence of SCD is more than
3 million people in the world per year. It means about 200–400
thousand in the U.S. population per year and in Europe it
accounts for about 2500 deaths per day. Nevertheless, the SCD
incidence in the general population is low (0.1–0.2% per year,ch Society of Cardiology.
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z (I. Andrsˇov a).i.e. 1–2 patients/1000 population). Approximately 50% of all
coronary heart disease deaths are sudden [1]. In most cases,
the underlying cause of death is the rapid onset of lethal
ventricular arrhythmias in the setting of acquired heart
disease. In our study we considered the common knowledge,
that the risk of sudden cardiac death is higher in patients
with structural heart disease (it means chronic ischemic
heart disease or dilated cardiomyopathy) and with systolicPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
gy, University Hospital Brno, Jihlavska 20, Brno 62500,
Table 1 – Clinical characteristics of investigated individuals.
Arrhythmic storm CAD controls p
(n ¼ 36) (n ¼ 141)
Male/female 33/3 129/12 0,4676
Age (years) 69,4711,4 66,7710,7 0,4610
Left ventricle ejection fraction 3279% 4279% o0,0001
CAD 69% 100% o0,0001
History of myocardial infarction 21(58%) 129(90%) o0,0001
dCMP 11(31%) 0 o0,0001
CAD ¼ coronary artery disease. dCMP ¼ dilated cardiomyopathy.
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showed that during 3 years only one third of patients with
primary preventive implantation of ICD needed the therapy
from the device due to malignant arrhythmias. The remain-
ing two thirds of patients were only ICD carriers [2].
Observations from population-based studies demonstrate a
strong genetic component of SCD [3–6]. It is clear that there
must be genetically determined variations of physiological
processes that increase the risk of SCD. It is well known that
myocardial ion channel gene mutations lead to increased SCD
risk in patients with relatively rare diseases, such as long QT
syndrome (LQTS), Brugada syndrome and catecholaminergic
polymorphic ventricular tachycardia (CPVT).
Ventricular premature complexes (VPCs) could initiate
malignant arrhythmias. High occurrence of VPCs is typical
for rare hereditary disease called CPVT. For this disorder
stress syncope or sudden cardiac death are typical, mani-
fested in young patients most often before 40 years of age.
The mortality is high, almost 50%. Mutations of RyR2 gene are
found in about 60% of patients with clinical diagnosis of CPVT
[7]. An important fact is that the resting ECG is completely
normal. But during stress VPCs become more frequent and
can progress in typical bidirectional ventricular tachycardia.
In our study we tried to test the hypothesis, that mutation of
RyR2 receptor could increase the risk of malignant arrhyth-
mias in patients with structural heart disease.2. Methods
2.1. Investigated subjects
The investigated group consisted of 36 Caucasian patients
from the region of south Moravia in the Czech Republic. These
individuals were identified from the ICD registry of our
department, partially retrospectively (years 1998–2006) and
from 2007 new consecutive patients were included prospec-
tively. The inclusion criteria were: (1) history of arrhythmic
storm defined as 3 or more sustained ventricular tachyar-
rhythmias within 24 h detected and treated from ICD. (2)
structural heart disease such as dilated cardiomyopathy
(dCMP) or CAD verified by echocardiography and coronary
angiography.
The control group consisted of 141 patients with CAD who
were hospitalized at our department owing to an acute
coronary event. For all patients the diagnosis was confirmedby coronary angiography. All patients had depressed left
ventricle ejection fraction (LVEF) and they were alive at least 3
years after the index event. Thus, they could be considered as
a CAD group with a low risk of SCD. Clinical characteristics of
both groups are summarized in Table 1.
Informed consent was obtained from all patients and
peripheral blood samples were taken for genomic DNA
preparation. The study protocol was approved by Ethical
Committee of the University Hospital Brno and conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.
2.2. Mutation analysis
Mutation analysis of the RyR2 gene was performed in all
members of the arrhythmic storm group. Genomic DNA
samples were isolated from peripheral blood lymphocytes
and PCR amplified fragments covering hot spot areas of RyR2
exons 2–4, 6–15, 17–20, 39–49, 83, 84, 87–97–105 were analyzed
by direct sequencing on the instrument ABI PRISM 3130 (Life
Technologies, USA). For mapping of exons 3, 97 and 105
deletions multiplex ligation-dependent probe amplification
analysis (MLPA) was used. Detailed methodology has been
described elsewhere [8–10]. The regions containing sequence
variants found in the arrhythmic storm group were se-
quenced in the control group of 141 patients with CAD
without arrhythmias.
2.3. Statistics
Values are given as mean7SD. Demographic data were
analyzed by the F test for variance and Student’s t-test. The
distributions of allelic frequencies and their differences were
calculated using w2 tests. The program package Statistica v. 8.0
(Statsoft Inc., Tulsa, OK, USA) was used for all statistical
analyses.3. Results
We detected 16 different sequence changes in both groups.
Twelve of these DNA changes were already described in the
study of Bagattin et al. [11] or in the database Ensemble [12].
The other have not been described yet. None of the found
nucleotide polymorphisms led to amino acid changes and
were located close to splice sites or had any similarity to
known splicing enhancer motifs. The occurrence of these
Table 2 – RyR2 gene variants in investigated # individuals.
Nucleotide change Exon/intron Allelic frequency (%) p References
Arrhythmic
storm (n ¼ 36)
Control
group (n ¼ 141)
c.[268100G4T] intron 3–4 4,0 6,2 0,5414 –
c.[4588A4C] intron 7–8 16,2 12,1 0,2991 12
c.[67111T4A] intron 9–10 43,2 53,8 0,1003 12
c.[100031T4A] intron 12–13 1,3 2,7 0,4860 –
c.[1353C4T] exon 15 33,8 40,5 0,2708 12
c.[6682þ72T4G] intron 43–44 36,5 47,0 0,0924 12
c.[6682þ93C4A] intron 43–44 27,0 16,2 0,0487 –
c.[6900T4C] exon 45 94,5 87,8 0,1117 13
c.[1132023C4T] intron 82–83 35,1 29,7 0,4182 12
c.[12957T4C] intron 89–90 58,1 68,9 0,0928 –
c.[13470þ16A4G] intron 92–93 33,8 28,3 0,4091 12
c.[13470þ47G4A] intron 92–93 36,5 43,2 0,2722 12
c.[1377721G4A] intron 94–95 55,4 42,5 0,0479 12
c.[137776A4G] intron 94–95 50,0 36,2 0,0318 12
c.[13907þ12A4C] intron 95–96 59,5 46,0 0,0390 12
c.[14085(1122delT)] intron 97–98 47,3 40,8 0,3231 –
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 8 4 – e 8 7e86variants was not different in both groups. The results are
summarized in Table 2.4. Discussion
In the present study, we performed a mutation analysis of a
cardiac ion-channel gene important in arrhythmogenesis. We
test the hypothesis that mutation of RyR2 gene could increase
risk of malignant arrhythmias in patients with structural
heart diseases. Our hypothesis was based on findings of
previous population studies that demonstrated a strong
genetic component of SCD.
Recently, several studies have investigated the issue of the
influence of genetic variants on the risk of arrhythmias in
patients with structural heart diseases. In these studies the
prevalence of rare coding variants in so called long QT genes
was significantly higher in patients suffering from ventricular
fibrillation as compared to control group [13–15].
The RyR2 gene was chosen because of its well known role in
the arrhythmogenesis in CPVT. This disease is characterized
by high occurrence of VPCs. We hypothesized that such RyR2
mutations can exist which usually remain latent, but under
stress conditions, such as structural heart disease, they can
increase the risk of ventricular arrhythmias also in normal
population.
The RyR2 gene is one of the largest genes in the human
genome and its analysis is time consuming. The majority of
mutations appear to cluster in three regions of the predicted
RyR2 protein topology, and about 65% of published mutations
of the RyR2 gene are located in these regions [9,16]. Therefore
we used a tiered targeting strategy suggested by groups in the
Mayo Clinic and the Netherlands [9]. Although we expected
only rare finding of sequence changes of RyR2 gene, the
opposite was true. The occurrence of sequence variants was
common in both groups. This suggests that these regions are
probably rather polymorphic in population. In our study 16sequence changes of RyR2 gene were detected in both groups.
None of the found nucleotide polymorphisms led to amino
acid changes, and were located close to splice sites or had any
similarity to known splicing enhancer motifs. Nevertheless,
there is emerging evidence that even synonymous DNA
variants can play important role in protein structure changes.
On the other side there were no statistical differences in their
allelic frequencies, thus the probability of any functional
effect of these variants is low.
The most important limitation of our study is the small
number of investigated individuals. Although the control
group was age and sex matched and all the control
individuals have depressed left ventricular systolic function
and coronary artery disease confirmed by angiography, there
were differences in ejection fraction and the etiology of heart
failure. This could have possible impact on the results.
Nevertheless, the prevalence of DNA variants was high also
in the control group. Using the tiered targeting strategy of
RyR2 gene mutation analysis can have an impact on the
robustness of the estimate of the prevalence of RyR2
mutations among the cohort. Due to the small number of
women included in the present study, it was not possible to
perform any sex-related associations.5. Conclusions
The prevalence of RyR2 gene variants was not different in
cases versus controls suggesting a limited role of this gene in
the arrhythmogenesis in structural heart disease patients.Acknowledgment
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